respiratory
Asthma

Our evolving understanding of severe asthma

Sponsored by Sanofi-aventis Australia Pty ltd

This is the first of three features in the limbic reporting on the ADVENT Advances in Type 2 Inflammatory Diseases medical education series run by Sanofi Genzyme. Previously, asthma was considered a homogenous disorder. Now, asthma is recognized by the Global Initiative for Asthma (GINA) Guidelines as a heterogenous disease, usually characterised by chronic airway ...

Already a member?

Login to keep reading.


OR
© 2020 the limbic